

October 28, 2020

Q2FY21 Result Update

Key Financials				
Y/e March	FY20	FY21E	FY22E	FY23E
Net Premiums (Rs m)	3,28,790	3,33,996	3,37,791	3,52,963
- Growth (%)	7.5	1.6	1.1	4.5
Surplus / Deficit (Rs m)	23,184	19,393	18,171	20,078
PAT (Rs m)	10,687	18,414	20,195	21,177
- Growth (%)	(6.3)	72.3	9.7	4.9
EPS (Rs)	7.4	12.8	14.1	14.7
Emb. Value (Rs bn)	230.3	267.2	307.3	352.1
NBP Margin (%) post overrun	21.7	25.8	25.9	25.7
RoE (%)	15.0	21.8	19.4	17.6
Operating RoEV (%)	15.2	15.2	15.1	14.7
RoEV (%)	6.5	16.0	15.0	14.6
Dividend (%)	8.0	-	17.0	17.0
Price/EV (x)	1.9	1.7	1.4	1.3
Ap. Value/EV (x)	2.1	2.0	1.9	1.9

Key Data	ICIR.BO IPRULIFE IN
52-W High / Low	Rs.538 / Rs.222
Sensex / Nifty	40,522 / 11,889
Market Cap	Rs.591.9bn/ \$ 8,029.2m
Shares Outstanding	1,435.9m
3M Avg. Daily Value	Rs.886.5m

Shareholding Pattern (%)

Promoter's	73.48
Foreign	15.78
Domestic Institution	4.63
Public & Others	6.11
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(2.4)	7.2	(16.6)
Relative	(8.9)	(19.6)	(17.8)

Pritesh Bumb

priteshbumb@plindia.com | 91-22-66322232

Aashi Rara

aashirara@plindia.com |

ICICI Prudential Life Insurance Company (IPRULIFE) Rating: HOLD | CMP: Rs412 | TP: Rs438

Continued margin tailwinds

Quick Pointers:

- Margins continues to show uptick and stood at 27.3% in Q2FY21 and 26.3% for H1FY21, a strong 630bps & 188bps improvement for Q2FY21 & H1FY21
- Growth was driven by Non-par savings, while protection also saw strong improvement in growth

ICICI Pru Life's delivered a strong uptick in margins to 27.4% in Q2FY21 & 26.3% on H1FY21 basis which was up 295bps QoQ improvement and is up 188bps up from Q1FY21 to H1FY21 basis. Tailwinds on margins have been on healthy mix change towards non-par savings & protection, while re-pricing benefit & opex control also help deliver margins. Protection share is now 19% in APE mix, although it is still lagging to peers with de-growth of 18% YoY in Q2FY21 & 10% YoY in H1FY21. Though margins have been strong, we believe margins will not sustain due to recovery in ULIP post Q4FY21, retraction of some repricing on protection due to competition & non-par savings growth will slow and hence see margins at 25-26% but are higher than 24% estimated earlier. We upgrade to HOLD from Reduce revised TP of Rs438 (from Rs425) based on 1.9x Sep-22 EV & 15x NBP.

- VNB turns flat in Q2FY21 on strong margin uptick: VNB stood at Rs4.0bn flat YoY/1x QoQ growth in Q2FY21, while still stood 15% lower in H1FY21 at Rs6.0bn. VNB improvement was on back of strong margins improvement to 27.3% in Q2FY21 & 26.3% in H1FY21 which has been continuing to move up from 21% seen last year. Improvement has been on mix change with ULIP out of flavor and Non par savings (guaranteed/annuities) & protection seeing relatively better growth. Margins have been on good uptrend despite growth being lower, although in our view margins should retract lower as ULIP sees growth, slower non-par savings growth and protection growth has lagged peers due to heavy competition and hence we believe 25% margins will be more sustainable.
- Optical mix changes but strong recovery sequentially: GWP grew by 7% YoY/52% QoQ led by single & renewal premium, while regular premium still struggling. Slower regular premium is also reflection of slower retail premium growth. Overall APE growth is still down 34% YoY in H1FY21 and will require strong growth in H2FY21 to see material improvement and should have base effect recovery in ULIP which is at 46% in APE mix. Protection mix stood at 19.5% but growth has remained laggard as compared to peers with de-growth of 10% YoY in H1FY21, we believe protection should continue to slowly improve but growth landscape remains extremely competitive.
- Steady earnings; persistency shows improvement: Earnings came in at steady Rs3.0bn led from steady underwriting & investment profits and recovery in premium sequentially. Persistency ratios remains improved as renewal growth was good. 13th month retail persistency on 5M basis was up 30bps to 82.1%, while 61st month was up 70bps QoQ to 57.5%. 13th month persistency is still lower than assumptions and hence we closely look at any assumption changes especially for ULIP.

(Rs m)	Q2FY21	Q2FY20	YoY gr. (%)	Q1FY21	QoQ gr. (%)
Policyholders' Account					
Gross Premium Income	87,335	81,908	6.6	57,467	52.0
Net Premium Income	85,722	80,647	6.3	55,511	54.4
Inc. from Investments (Net)	79,494	(1,269)	NA	130,672	(39.2)
Total (A)	168,354	82,091	105.1	190,574	(11.7)
Net Commission	3,499	3,945	(11.3)	2,067	69.2
Opex related to Insurance	6,400	7,542	(15.1)	4,939	29.6
Benefits Paid (Net)	49,097	41,373	18.7	25,961	89.1
Change in actuarial liability	101,978	21,583	372.5	149,428	(31.8)
Total (B)	162,962	77,323	110.8	184,263	(11.6)
Surplus / (Deficit)	5,391	4,768	13.1	6,311	(14.6)
Shareholders' Account					
Trf from Policyholders A/c	4,531	3,966	14.3	6,461	(29.9)
Investment Income	1,691	2,047	(17.4)	1,274	32.7
Total	6,226	6,015	3.5	7,737	-19.5
Expenses other than related to insurance	22	73	(69.9)	176	(87.5)
Trf to Policyholders A/c	2,895	2,521	14.8	4,163	(30.5)
Profit/(Loss) before Tax	3,299	3,063	7.7	3,112	6.0
Provision for Taxation	267	45	496.4	236	13.2
Profit/(Loss) after Tax	3,032	3,019	0.5	2,876	5.4
Ratios					
Expense Ratio	9.0	10.6	(167)	10.2	(117)
Commission Ratio	4.9	5.6	(66)	4.2	66
Cost / TWRP	13.9	16.2	(232)	14.4	(50)

Exhibit 1: Premium recovery, underwriting profits help retain steady earnings

Source: Company, PL

Exhibit 2: Overall APE still de-growing but recovers sequentially due to savings

	Q2FY21	Q2FY20	YoY gr. (%)	Q1FY21	QoQ gr. (%)	H1FY21	H1FY20	YoY gr. (%)
APE	14,650	18,990	(22.9)	8,230	78.0	22,880	33,690	(32.1)
Savings	12,330	16,170	(23.7)	6,090	102.5	18,420	28,720	(35.9)
Protection	2,320	2,820	(17.7)	2,140	8.4	4,460	4,970	(10.3)
%								
Savings	84.2	85.2	(99)	74.0	1,017	80.5	85.2	(474)
Protection	15.8	14.8	99	26.0	(1,017)	19.5	14.8	474
VNB	4,010	4,000	0.2	2,010	99.5	6,020	7,090	(15.1)
VNB Margin (%)	27.4	21.1	630.8	24.4	294.9	26.3	21.0	530.0

Source: Company, PL

P

Exhibit 3: Renewal & group premium grows well, while retail is still de-growing

	Q2FY21	Q2FY20	YoY gr. (%)	Q1FY21	QoQ gr. (%)	H1FY21	H1FY20	YoY gr. (%)
Retail renewal premium	54,730	51,500	6.3	41,070	33.3	95,800	91,260	5.0
Retail new business premium	17,490	20,710	(15.5)	9,120	91.8	26,610	36,040	(26.2)
Group Premium	10,610	9,690	9.5	7,280	45.7	17,890	17,890	-
Total	82,830	81,900	1.1	57,470	44.1	140,300	145,190	(3.4)

Source: Company, PL


ICICI Prudential Life Insurance Company

Product Mix	Q2FY21	Q2FY20	YoY gr. (%)	Q1FY21	QoQ gr. (%)	H1FY21	H1FY20	YoY gr. (%)
Rs Mn								
Savings	12,330	16,170	(23.7)	6,090	102.5	18,420	28,730	(35.9)
ULIP	7,010	12,760	(45.1)	3,590	95.3	10,600	23,220	(54.3)
Par	4,658	2,190	112.7	1,762	164.4	6,420	3,610	77.8
Non PAR	(248)	280	(188.6)	248	(200.0)	-	480	(100.0)
Group	910	940	(3.2)	490	85.7	1,400	1,420	(1.4)
Protection	2,320	2,830	(18.0)	2,140	8.4	4,460	4,970	(10.3)
(%)								
Savings	84.2	85.2	(99)	74.0	1,017	80.5	85.3	(477)
ULIP	47.8	67.2	(1,934)	43.6	423	46.3	68.9	(2,259)
Par	31.8	11.5	2,026	21.4	1,039	28.1	10.7	1,734
Non PAR	(1.7)	1.5	(317)	3.0	(471)	-	1.4	(142)
Group	6.2	4.9	126	6.0	26	6.1	4.2	190
Protection	15.8	14.9	93	26.0	(1,017)	19.5	14.8	474

Exhibit 4: Protection biz. continues robust share gain; Savings dragged down due to ULIP

Source: Company, PL

Exhibit 5: Mix continuously shifting to protection



Source: Company, PL

Exhibit 6: Banca channel has remained slow

Sourcing Mix	Q2FY21	Q2FY20	YoY gr. (%)	Q1FY21	QoQ gr. (%)	H1FY21	H1FY20	YoY gr. (%)
Rs Mn								
Banca	6,410	10,100	(37)	3,260	97	9,670	17,800	(46)
Agency	3,320	3,760	(12)	2,030	64	5,350	6,870	(22)
Direct	1,780	2,470	(28)	1,010	76	2,790	4,350	(36)
Corp Agent & Brokers	1,260	1,390	(9)	710	77	1,970	2,390	(18)
Group	1,870	1,270	47	1,230	52	3,100	2,270	37
(% Mix)								
Banca	43.8	53.2	(943)	39.6	414	42.3	52.8	(1,057)
Agency	22.7	19.8	286	24.7	(200)	23.4	20.4	299
Direct	12.2	13.0	(86)	12.3	(12)	12.2	12.9	(72)
Corp Agent & Brokers	8.6	7.3	128	8.6	(3)	8.6	7.1	152
Group	12.8	6.7	608	14.9	(218)	13.5	6.7	681

Source: Company, PL





Exhibit 7: Banca share has been coming off while Group inches ahead


Source: Company, PL

Exhibit 8: Lower sales help improve Commission Ratios



Source: Company, PL

Exhibit 9: Persistency improves in Q2FY21



Source: Company, PL




Exhibit 10: Solvency ratio improves on recovery in equity markets

Source: Company, PL

Exhibit 11: Key Metrics and EV movement

Rs bn	FY18	FY19	FY20	FY21E	FY22E	FY23E
APE	77.9	78.0	73.8	63.3	73.1	81.5
YoY growth (%)	17.6	0.1	(5.4)	(14.2)	15.6	11.4
NBV	12.9	13.3	16.1	16.3	19.0	20.9
YoY growth (%)	93.1	3.3	20.9	1.6	16.3	10.5
EV Movement						
Opening IEV	161.8	187.9	216.3	230.3	267.2	307.3
New Business Value	36.8	13.3	16.1	16.3	19.0	20.9
EVOP	12.9	38.0	32.9	34.9	40.4	45.1
Dividend pay-out	11.9	8.4	4.1	-	5.3	5.3
Closing EV	187.9	216.3	230.3	267.2	307.3	352.1
Adjusted Net worth	70.2	73.5	78.4	96.7	112.0	128.2
Value in force (VIF)	117.6	142.7	151.9	170.5	195.3	223.9
Ratios (%)						
NBAP margins	16.5	17.0	21.7	25.8	25.9	25.7
RoEV	16.1	15.1	6.5	16.0	15.0	14.6
Operating RoEV	22.7	20.2	15.2	15.2	15.1	14.7

Source: Company, PL

Exhibit 12: Change in Estimates - We increase margins & improve growth

(De hr)		Old			Revised		%	6 Change	
(Rs bn)	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
APE	62.9	70.5	77.8	63.3	73.1	81.5	0.6	3.8	4.8
VNB	15.4	17.3	19.2	16.3	19.0	20.9	5.7	9.8	9.3
VNB Margin (%)	24.5	24.5	24.6	25.8	25.9	25.7	1.3	1.4	1.1
EV	261.9	299.6	341.8	267.2	307.3	352.1	2.0	2.6	3.0
Price target (Rs)		425			438			3.1	
Recommendation	F	REDUCE			HOLD				

Source: Company, PL

P

PT calculation and upside Op RoEV 14.7% CoE 14.6% Terminal Growth 5.0% Embedded value - Sep'22 (Rs bn) 300 Appraisal Value - Sep'22 (Rs bn) 629 Price / Embedded Value 1.9 New Business Premium Multiple 15.0 Valuation per share 438 CMP 412 Upside (%) 6.4%

Exhibit 13: We revise our TP to Rs438 (from Rs425) based on 1.9x Sep FY22E

Source: Company, PL

P

ICICI Prudential Life Insurance Company

Fechnical account (Rs m)	EVOO	EV04E	EVOOF	EVODE
(/e Mar	FY20	FY21E	FY22E	FY23E
Gross Premiums	3,34,307	3,38,938	3,42,582	3,57,803
Reinsurance Ceded	(5,518)	(4,942)	(4,791)	(4,840)
Net Premiums Dther Income	3,28,790 608	3,33,996 695	3,37,791 793	3,52,963 906
Fotal income	2,19,395	4,59,284	4,96,626	5,36,620
Commission	15,860	16,195	4,30,020 16,744	17,525
Operating expenses	28,469	34,884	35,015	36,054
Prov for doubtful debts	2,151	2,437	2,760	3,126
Operating Profit	1,72,915	4,05,769	4,42,107	4,79,915
Prov for Tax	6,534	7,187	7,906	8,697
Benefits Paid (Net)	1,93,026	1,68,945	1,63,632	1,72,178
Chg in reserves	(50,569)	2,10,243	2,52,398	2,78,962
Surplus / Deficit	23,184	19,393	18,171	20,078
Shareholder's a/c (Rs m)				
Y/e Mar	FY20	FY21E	FY22E	FY23E
Fransfer from technical a/c	19,887	17,266	15,679	17,318
ncome From Investments	6,594	11,093	15,851	16,735
Fotal Income	26,487	28,365	31,537	34,060
Other expenses	364	436	524	628
Contribution to technical a/c	14,971	8,545	9,756	11,140
Total Expenses	15,800	8,981	10,279	11,768
РВТ	10,687	19,384	21,258	22,292
Prov for Tax	(0)	969	1,063	1,115
PAT	10,687	18,414	20,195	21,177
Promium (Do m) 8 growth (01)				-
Premium (Rs m) & growth (%)	EV/00	EVOLE	EVOOE	EVO2E
(/e Mar	FY20	FY21E	FY22E	FY23E
lew business prem - unwtd	1,24,875	1,27,373	1,33,741	1,43,103
New business prem - APE	71,283	63,299	73,148	81,518
Renewal premium	2,09,432	2,11,565	2,08,841	2,14,700
otal premium - unwtd	3,34,307	3,38,938	3,42,582	3,57,803
New bus. growth - unwtd	20.5	2.0	5.0	7.0
New business growth - APE	(2.6)	(11.2)	15.6	11.4
Renewal premium growth	1.8	1.0	(1.3)	2.8
otal prem growth - unwtd	8.1	1.4	1.1	4.4
Premium mix (%)				
//e Mar	FY20	FY21E	FY22E	FY23E
lew business - unwtd				
- Individual mix	63.1	80.0	80.0	80.0
- Group mix	36.9	20.0	20.0	20.0
lew business mix - APE				
- Participating	12.4	16.1	12.8	14.0
- Non-participating	18.8	33.4	27.0	24.0
- ULIPs	68.7	50.5	60.2	62.0
Fotal premium mix - unwtd				
- Participating	12.0	11.1	10.7	11.(
- Non-participating	18.1	30.5	28.8	27.6
- ULIPs	69.8	58.3	60.5	61.4
ndividual prom courcing mix (%)				
ndividual prem sourcing mix (%)		EVOLE	EVODE	EVOOR
Y/e Mar	FY20	FY21E	FY22E	FY23E
ndividual agents	21.9	19.0	19.0	19.0
Corporate agents-Banks	49.7 20.1	62.0	62.0	62.0
Direct business	20.1	11.0	11.0	11.0
Others	8.3	8.0	8.0	8.0

Balance sheet (Rs m)							
Y/e Mar	FY20	FY21E	FY22E	FY23E			
Sources of Fund	1120	11216	TIZZE	TIZJE			
Share Capital	14,359	14,359	14,359	14,359			
Reserves And Surplus	61,056	79,470	94,353	1,10,217			
Policy Liabilities	4,73,556	5,24,393	6,06,406	7,54,741			
Prov. for Linked Liab.	8,80,368	11,35,894	13,06,278	14,36,906			
Funds For Future App.	12,327	13,559	14,915	16,407			
Current liabilities & prov.	33,304	30,042	27,117	24,496			
Total	15,60,353	18,07,585	20,75,216	23,71,271			
Application of Funds							
Shareholders' inv	74,209	1,77,902	1,82,358	1,97,985			
Policyholders' inv	4,67,503	4,43,641	5,33,888	6,80,939			
Assets to cover linked liab.	9,70,850	11,35,894	13,06,278	14,36,906			
Loans	4,631	5,094	5,603	6,164			
Fixed Assets	4,776	5,254	5,779	6,357			
Current assets	38,384	39,800	41,309	42,920			
Total	15,60,353	18,07,585	20,75,216	23,71,271			
Operating ratios							
Y/e Mar	FY20	FY21E	FY22E	FY23E			
Investment yield (%)	(8.7)	7.4	8.1	8.1			
Commissions / GWP	4.7	4.8	4.9	4.9			
- first year premiums	17.5	19.4	17.4	23.5			
- renewal premiums	1.8	2.0	2.0	2.0			
- single premiums	1.1	1.5	1.5	1.5			
Operating expenses / GWP	8.5	10.3	10.2	10.1			
Total expense ratio	13.3	15.1	15.1	15.0			
Claims / NWP	58.7	50.6	48.4	48.8			
Solvency margin	111.6	251.0	266.2	278.4			
Persistency ratios (%)							
Y/e Mar	FY20	FY21E	FY22E	FY23E			
13th Month	86.8	86.7	86.7	86.7			
25th Month	78.3	77.8	77.7	77.7			
37th Month	70.1	70.3	70.0	69.9			
49th Month	67.3	66.8	66.9	66.8			
61st Month	58.7	59.1	59.0	59.0			
Profitability ratios (%)							
Y/e Mar	FY20	FY21E	FY22E	FY23E			
NBP margin (%) pre overrun	-	-	-	-			
NBP margin (%) post overrun	21.7	25.8	25.9	25.7			
RoE (%)	15.0	21.8	19.4	17.6			
RoIC (%)	22.0	37.9	41.5	43.5			
Valuation ratios							
Y/e Mar	FY20	FY21E	FY22E	FY23E			
Total AUMs, Rs bn	1,530	1,757	2,023	2,316			
- of which equity AUMs (%)	39.9	46.0	46.0	46.0			
EVOP as % of MCEV	15.2	15.2	15.1	14.7			
RoEV (%)	6.5	16.0	15.0	14.6			
Dividend %	8.0	-	17.0	17.0			
Dividend payout ratio (%)	38.1	-	26.3	25.1			
EPS, Rs	7.4	12.8	14.1	14.7			
Embedded Value, Rs bn	230.3	267.2	307.3	352.1			
Appraisal value/EV (x)	2.1	2.0	1.9	1.9			
Appraisal value/Net profit (x)	44.82	29.11	29.53	31.28			
Source: Company Data, PL Research							

ICICI Prudential Life Insurance Company

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Axis Bank	Hold	480	468
2	Bank of Baroda	BUY	65	44
3	Federal Bank	BUY	69	52
4	HDFC Bank	BUY	1,385	1,203
5	HDFC Life Insurance Company	Reduce	533	571
6	ICICI Bank	BUY	462	402
7	ICICI Prudential Life Insurance Company	Hold	424	434
8	IDFC First Bank	Sell	21	32
9	IndusInd Bank	BUY	680	623
10	Kotak Mahindra Bank	Accumulate	1,503	1,417
11	Max Financial Services	Accumulate	651	610
12	Punjab National Bank	BUY	40	29
13	SBI Life Insurance Company	BUY	920	779
14	South Indian Bank	BUY	10	7
15	State Bank of India	BUY	276	198

PL's Recommendation Nomenclature (Absolute Performance)

:	>15%
:	5% to 15%
:	+5% to -5%
:	-5% to -15%
:	< -15%
:	No specific call on the stock
:	Rating likely to change shortly
	: :



ANALYST CERTIFICATION

(Indian Clients)

We/l, Mr. Pritesh Bumb- MBA, M.com, Ms. Aashi Rara- CA, B.Com Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Pritesh Bumb- MBA, M.com, Ms. Aashi Rara- CA, B.Com Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not regulatory licensing requirements of FINRA or required to otherwise company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com